Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy

• Verfasst von: Xiong, Yingquan [VerfasserIn]
• Verfasst von: Delic, Denis [VerfasserIn]
• Verfasst von: Zeng, Shufei [VerfasserIn]
• Verfasst von: Chen, Xin [VerfasserIn]
• Verfasst von: Chu, Chang [VerfasserIn]
• Verfasst von: Hasan, Ahmed A. [VerfasserIn]
• Verfasst von: Krämer, Bernhard [VerfasserIn]
• Verfasst von: Klein, Thomas [VerfasserIn]
• Verfasst von: Yin, Lianghong [VerfasserIn]
• Verfasst von: Hocher, Berthold [VerfasserIn]
• Titel: Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy
• Titelzusatz: effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker
• Verf.angabe: Yingquan Xiong, Denis Delic, Shufei Zeng, Xin Chen, Chang Chu, Ahmed A. Hasan, Bernhard K. Krämer, Thomas Klein, Lianghong Yin and Berthold Hocher
• E-Jahr: 2022
• Jahr: 24 March 2022
• Umfang: 10 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 07.05.2024
• Titel Quelle: Enthalten in: BMC nephrology
• Ort Quelle: London : BioMed Central, 2000
• Jahr Quelle: 2022
• Band/Heft Quelle: 23(2022), Artikel-ID 117, Seite 1-10
• ISSN Quelle: 1471-2369
• DOI: doi:10.1186/s12882-022-02747-1
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1887965165

Abstract

Host factors such as angiotensin-converting enzyme 2 (ACE2) and the transmembrane protease, serine-subtype-2 (TMPRSS2) are important factors for SARS-CoV-2 infection. Clinical and pre-clinical studies demonstrated that RAAS-blocking agents can be safely used during a SARS-CoV-2 infection but it is unknown if DPP-4 inhibitors or SGLT2-blockers may promote COVID-19 by increasing the host viral entry enzymes ACE2 and TMPRSS2. We investigated telmisartan, linagliptin and empagliflozin induced effects on renal and cardiac expression of ACE2, TMPRSS2 and key enzymes involved in RAAS (REN, AGTR2, AGT) under high-salt conditions in a non-diabetic experimental 5/6 nephrectomy (5/6 Nx) model. In the present study, the gene expression of Ace2, Tmprss2, Ren, Agtr2 and Agt was assessed with qRT-PCR and the protein expression of ACE2 and TMPRSS2 with immunohistochemistry in the following experimental groups: Sham + normal diet (ND) + placebo (PBO); 5/6Nx + ND + PBO; 5/6Nx + high salt-diet (HSD) + PBO; 5/6Nx + HSD + telmisartan; 5/6Nx + HSD + linagliptin; 5/6Nx + HSD + empagliflozin. In the kidney, the expression of Ace2 was not altered on mRNA level under disease and treatment conditions. The renal TMPRSS2 levels (mRNA and protein) were not affected, whereas the cardiac level was significantly increased in 5/6Nx rats. Intriguingly, the elevated TMPRSS2 protein expression in the heart was significantly normalized after treatment with telmisartan, linagliptin and empagliflozin. Our study indicated that there is no upregulation regarding host factors potentially promoting SARS-CoV-2 virus entry into host cells when the SGLT2-blocker empagliflozin, telmisartan and the DPP4-inhibitor blocker linagliptin are used. The results obtained in a preclinical, experimental non-diabetic kidney failure model need confirmation in ongoing interventional clinical trials.